Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study resulted in a draft version of the Patient‐Reported Impact of Dermatological Diseases measure, PRIDD, which includes 27 items refined from patient consensus and is now undergoing psychometric testing.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

This study reported that the AAPPO tool effectively distinguishes between patients with alopecia areata based on scalp hair loss severity, whereas the EQ‐5D‐5L may underestimate the specific disease burden, particularly in psychological and social aspects.

In this study, patients with more severe self-reported hair loss and emotional or social limitations experienced lower quality of life and greater work productivity impairment, with even moderate hair loss causing significant well-being and daily activity impacts.

In this study, a Delphi survey among 441 European dermatology patients identified psychological impacts as the most significant issues affecting their lives, underscoring the need for psychological support in managing dermatological diseases.